Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
Daiichi Sankyo2020-08-03 09:33:03Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol
-
Daiichi Sankyo2020-08-03 09:33:40Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral,
-
Daiichi Sankyo2020-08-03 09:34:15Bempedoic Acid Study 1 results published in The New England Journal of Medicine demonstrated significant
-
Daiichi Sankyo2020-08-03 09:35:00Daiichi Sankyo Announces New Data on Once-Daily LIXIANA®▼ (edoxaban) to be Presented in Late-Breaking Sessions
-
Daiichi Sankyo2020-08-03 09:35:39Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for
-
Daiichi Sankyo2020-08-03 09:36:09Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the